Tag: "max" at medical news

First head-to-head trials of once weekly Fosamax and Actonel therapies

The drug major Merck has launched the first two head-to-head clinical trials that compare the efficacy and tolerability of Fosamax (alendronate) once weekly 70mg and Actonel (risedronate) once-weekly 35mg. Fosamax and Actonel, both bisphosphonates indicated for the treatment of osteoporosis in post menopausal women are co-marketed by Aventis and Procter & Gamble through the Alliance for// Better...

Comfort Level, Maximum in Ethnically Diverse Schools

Middle school students have expressed a high degree of comfort level in ethnically diverse schools, as the environment in these schools are safer// , and make the students feel wanted. Students are not subjected to bullying as much, compared to other schools. ..'Bullying happens in every school, and many students are concerned about their safe...

Saket Hospital to get Multi-speciality Facilities from Max Healthcare

Max Healthcare Thursday opened its sixth hospital in the capital to offer multi-speciality facilities under one roof//. ....Together with the new 200-bed Max Super Speciality Hospital, the Saket hospital complex of Max will now offer 450 bed facility along with the most advanced neurosurgery department equipped with Asia's the first Brain Suite. ....'Except oncology, the Max hospital complex at...

Max Healthcare Launches Outpatient Health Plans

Targeting an area uncovered by health insurance, leading hospital chain Max Healthcare Wednesday formally launched a modular outpatient plan offering benefits of a family// physician, specialists and diagnostics facilities under a pre-paid annual package. ....Simultaneously, the hospital chain that is aiming to raise the number of facilities in the national capital region to nine from present mu...

Max Planck Researchers Incorporate Odorant Receptors into Artificial Membranes

An artificial nose could be a real benefit at times: this kind of biosensor could sniff out poisons, explosives or drugs//, for instance. ....Researchers at the Max Planck Institute for Polymer Research and the Max Planck Institute of Biochemistry recently revealed a technique for integrating membrane proteins into artificial structures. ....Membrane proteins have several important functions...

International Study Finds Ways to Maximize Effective Responses After Terrorism Incidents

A multi-disciplinary panel of blast-related injury experts from eight countries that have recently experienced terrorist attacks examined// and discussed their emergency medical response to blast events and identified common issues that could be used by others to enhance preparedness. ....According to...

Kolkata, Mumbai to Face Maximum Brunt of Climate Change

Mumbai and Kolkata will be the worst sufferer among Indian cities with flash rains, floods and fall in water tables as well as water conservation //potential, says an international report on climate change. ....According to the fourth assessment report by the Intergovernmental Panel on Climate Change (IPCC), the rise in sea level and flooding of villages would become a regular affair in the near...

Climate Change Poses Maximum Threat to Public Life in Developing Countries

Climate change poses the maximum threat to public health in the developing countries, has said a recent study in Springer's Journal of Urban Health , despite the fact that they have contributed the least to greenhouse gas emissions. ......"The rapid economic development and the concurrent urbanization of poorer countries mean that developing-country cities will be both vulnerable to health hazar...

IFC to Invest About Rs.3 Billion in Max Healthcare

International Finance Corp. (IFC), the private sector division of World Bank, Monday announced its plans to invest Rs.3 billion in India's Max Healthcare Institute for its expansion plans. ......Max Healthcare Institute is a subsidiary of Max India, a multi-business company with interests in life insurance, health care, clinical research, and specialty plastics. ........."While the government...

Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients

Maxygen, Inc. today announced that it has initiated a phase IIa trial to evaluate the efficacy, safety and tolerability of MAXY-G34 in the treatment of chemotherapy-induced neutropenia . MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) shown in preclinical and Phase I studies to have novel and potentially superior properties compared to the current PEG- GCSF therapy....